文献速递中枢神经肿瘤放疗放疗物理与技术

复发性颅内转移瘤重复HyperArc放射外科治疗及复发模式剂量学分析以解释弥漫剂量对显微病变的影响

Repeated HyperArc radiosurgery for recurrent intracranial metastases and dosimetric analysis of recurrence pattern to account for diffuse dose effect on microscopical disease.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-24

56例脑转移患者因颅内进展接受197次HyperArc治疗,共治疗702个转移灶。1年总生存率70%,中位总生存20.8个月;1年颅内无进展生存率15%,中位颅内无进展生存4.9个月。96.4%的新发脑转移发生在0-7 Gy等剂量线范围内(P=0.00)。放射性坏死发生率0.28%,无3级及以上临床毒性。

要点

  • 重复HyperArc治疗颅内复发性转移安全有效,可推迟或避免全脑放疗。
  • 96.4%新发脑转移出现在0-7 Gy等剂量线范围,提示弥漫低剂量可能减少显微病变。
  • 神经性死亡并非该人群最常见死因,颅外疾病控制影响总生存。

核心结论

  • 颅内复发可安全有效地采用重复HyperArc治疗,旨在推迟或避免全脑放疗。
  • 容积调强放疗的弥漫剂量可能在相对低剂量水平减少显微病变,潜在充当虚拟临床靶区。
  • 神经性死亡并非该人群最常见死因,凸显颅外疾病对总生存的影响。

研究设计与样本

  • 56例脑转移患者因孤立颅内进展接受197次HyperArc治疗(范围2-8次),共治疗702个脑转移灶。
  • 主要终点为总生存,次要终点包括颅内无进展生存、毒性、局部控制、神经性死亡和免全脑放疗生存。
  • 评估进展部位与等剂量线水平(0、1、2、3、5、7、8、10、13、15、20和24 Gy)的关系。

主要发现

  • 1年总生存率为70%,中位总生存20.8个月(17-36)。
  • 单因素分析显示生物等效剂量(BED)>51.3 Gy和非黑色素瘤组织学与总生存显著相关。
  • 中位颅内无进展生存4.9个月,1年颅内无进展生存率15%。
  • 首次HyperArc周期后,颅外疾病控制患者中共出现538个新发脑转移,其中96.4%发生在0-7 Gy等剂量线范围内:0 Gy占26.6%,1 Gy占16.5%,2 Gy占16.5%,3 Gy占20.1%,5 Gy占13.1%,7 Gy占3.4%(P=0.00)。
  • 放射性坏死发生于2个转移灶(0.28%),随访期间无3级及以上临床毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Evaluate effectiveness and safety of multiple HyperArc courses and patterns of progression in patients affected by BMs with intracranial progression. METHODS: 56 patients were treated for 702 BMs with 197 (range 2-8) HyperArc courses in case of exclusive intracranial progression. Primary end-point was the overall survival (OS), secondary end-points were intracranial progression-free survival (iPFS), toxicity, local control (LC), neurological death (ND), and whole-brain RT (WBRT)-free survival. Site of progression was evaluated against isodoses levels (0, 1, 2, 3, 5, 7, 8, 10, 13, 15, 20, and 24 Gy.). RESULTS: The 1-year OS was 70 %, and the median was 20.8 months (17-36). At the univariate analysis (UVA) biological equivalent dose (BED) > 51.3 Gy and non-melanoma histology significantly correlated with OS. The median time to iPFS was 4.9 months, and the 1-year iPFS was 15 %. Globally, 538 new BMs occurred after the first HA cycle in patients with extracranial disease controlled. 96.4 % of them occurred within the isodoses range 0-7 Gy as follows: 26.6 % (0 Gy), 16.5 % (1 Gy), 16.5 % (2 Gy), 20.1 % (3 Gy), 13.1 % (5 Gy), 3.4 % (7 Gy) (p = 0.00). Radionecrosis occurred in 2 metastases (0.28 %). No clinical toxicity of grade 3 or higher occurred during follow-up. One- and 2-year LC was 90 % and 79 %, respectively. At the UVA BED > 70 Gy and non-melanoma histology were significant predictors of higher LC. The 2-year WBRT-free survival was 70 %. After a median follow-up of 17.4 months, 12 patients deceased by ND. CONCLUSION: Intracranical relapses can be safely and effectively treated with repeated HyperArc, with the aim to postpone or avoid WBRT. Diffuse dose by volumetric RT might reduce microscopic disease also at relatively low levels, potentially acting as a virtual CTV. Neurological death is not the most common cause of death in this population, which highlights the impact of extracranial disease on overall survival.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nicosia L, Allegra AG, Giaj-Levra N, et al. Repeated HyperArc radiosurgery for recurrent intracranial metastases and dosimetric analysis of recurrence pattern to account for diffuse dose effect on microscopical disease. Clin Transl Radiat Oncol. 2024. PMID: 39036468. doi:10.1016/j.ctro.2024.100811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。